

Title (en)
METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS

Title (de)
VERFAHREN ZUR IDENTIFIZIERUNG THERAPEUTISCH EFFEKTIVER ANTINEOPLASTISCHER SUBSTANZEN MITTELS KULTIVierter ZELLEN MIT INTAKTEN ZELLMEMBRANEN UND DAMIT ZUSAMMENHÄNGENDE PRODUKTE

Title (fr)
TECHNIQUES D'IDENTIFICATION D'AGENTS ANTINEOPLASTIQUES THERAPEUTIQUEMENT EFFICACES AVEC DES CELLULES DE CULTURE A MEMBRANE CELLULAIRE INTACTE ET PRODUITS CORRESPONDANT

Publication
EP 1151295 A1 20011107 (EN)

Application
EP 00907081 A 20000201

Priority
• US 0002329 W 20000201
• US 11810299 P 19990201
• US 45459599 A 19991207

Abstract (en)
[origin: WO0045165A1] A method for identifying potentially therapeutically effective antineoplastic compounds comprising determining the ability of test compounds to act as activators of the caspase cascade in viable cultured eukaryotic cells having an intact cell membrane and expressing a cancer phenotype, wherein a test compound that enhances caspase cascade activity is determined to have potential therapeutic efficacy. The method specifically differentiates activators of the caspase cascade from non-specific cell poisons. A therapeutic method useful to modulate in vivo apoptosis or in vivo neoplastic disease, comprising administering to a subject an effective amount of a compound identified as a caspase cascade activator is provided. Compounds, pharmaceutical compositions and a kit for performing the therapeutic method are further provided.

IPC 1-7
G01N 33/50

IPC 8 full level
A61K 31/00 (2006.01); **A61K 31/352** (2006.01); **A61K 31/4025** (2006.01); **A61K 31/4178** (2006.01); **A61K 31/4188** (2006.01); **A61K 31/4433** (2006.01); **A61K 31/453** (2006.01); **A61K 31/475** (2006.01); **A61K 31/496** (2006.01); **A61K 31/5377** (2006.01); **A61K 31/5513** (2006.01); **A61K 31/675** (2006.01); **C07D 493/20** (2006.01); **C07D 493/22** (2006.01); **C07D 519/00** (2006.01); **C12Q 1/37** (2006.01); **G01N 33/50** (2006.01)

CPC (source: EP)
A61K 31/00 (2013.01); **A61K 31/352** (2013.01); **A61K 31/4025** (2013.01); **A61K 31/4178** (2013.01); **A61K 31/4188** (2013.01); **A61K 31/4433** (2013.01); **A61K 31/453** (2013.01); **A61K 31/475** (2013.01); **A61K 31/496** (2013.01); **A61K 31/5377** (2013.01); **A61K 31/5513** (2013.01); **A61K 31/675** (2013.01); **C07D 493/20** (2013.01); **C07D 493/22** (2013.01); **C07D 519/00** (2013.01); **C12Q 1/37** (2013.01); **G01N 33/5011** (2013.01); **G01N 2500/10** (2013.01)

Cited by
CN109862891A

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0045165 A1 20000803; AU 2864100 A 20000818; EP 1151295 A1 20011107; EP 1151295 A4 20050330

DOCDB simple family (application)
US 0002329 W 20000201; AU 2864100 A 20000201; EP 00907081 A 20000201